With the year 2020 in view, it’s critical for healthcare decision makers to have powerful resources and tools to identify and act on the most important factors shaping the market. Kantar’s latest edition of its annual Global Health and Wellness Report (GHWR) is one such dynamic tool.
The 2019 GHWR, titled "Healthcare 2020: The 10 Key Influencers of Global Health and Wellness," represents the voice of patients speaking on the true impact of 200 health conditions globally and has served for many years as the barometer for patient sentiment across the greater global healthcare community. It's unlike any other healthcare report and provides a clear line of sight to the most important factors shaping the highly-complex global healthcare market.
What makes the GHWR so powerful and unique is that its supported by Kantar's National Health and Wellness Survey and other proprietary data assets, delivering deeper insights into the “patient as a person” and enabling life sciences companies see the clinical, social and emotional effects of disease to support new treatments and help people live healthier lives.
The result is a comprehensive record of global health and incomparable patient insights on the most pressing health challenges for the United States, the EU5 (France, Germany, Italy, Spain and United Kingdom), Japan, and key Emerging Markets (Brazil, China and Russia).
Health industry stakeholders, including patients, caregivers, providers, employers and payers, as well as other important participants such as pharmaceutical and life sciences companies, patient advocacy groups and governmental agencies, will find great value in a better understanding of the magnitude of diseases and the many aspects of health-related outcomes – both within and across country lines.
10 Key Influencers
The 2019 edition of the GHWR identifies, and then comprehensively examines, 10 key influencers impacting global healthcare as we arrive at the year 2020 and a new decade. These 10 influencers include:
- Global Privacy Legislation – As Big Data becomes an even more dominant force, global privacy legislation is at the forefront of protecting people’s privacy while effectively balancing pharma and healthcare organizations’ continual need to stretch the limits of innovation. In our report, we examine how the global privacy landscape will continue to evolve as multinational and regional organizations push ahead with their quest for data.
- Linking Patient Data to Clinical and Electronic Health Records – To fully demonstrate the value proposition of their products to various constituents, life sciences and pharmaceutical companies need highly accurate and timely information from both the physician and patient’s perspectives. With patient input playing an increasingly important role in pharma decision-making, today there’s an increased focus on gaining a clearer picture of the patient from multiple angles. However, achieving this multi-angle view of the patient is highly complex. Kantar sought to solve this challenge by linking its syndicated patient reported outcomes (PRO) data with clinical data. We were successful, recently introducing ClaritisTM, a breakthrough approach to real world data analytics.
- Oncology Innovation – Perhaps one of the most exciting areas in healthcare today is oncology, as advanced, new therapies are emerging to treat cancer. For 2019, we examined the most interesting developments and trends in oncology, and several important clinical trials we believe are critical to patients and the industry.
- Vaccines – Disease prevention is an important component to effectively managing healthcare costs. Vaccines play a critical role in disease prevention, as aggressively vaccinating susceptible populations protects public health, promotes a healthy environment and keeps healthcare costs down. However, whereas a major challenge a decade ago may have been to increase vaccination rates in emerging countries and markets, today industry is working to maintain vaccination rates in Western countries, where rates have surprisingly fallen and given rise to epidemics for diseases once deemed in check.
- Medicine Adherence and 'Patient Modes' – To drive better medicine adherence and improve patient health, life sciences companies and pharmaceutical manufacturers need to put greater emphasis on the individual person’s health journey and achieve a better understanding of ‘patient modes’. Modes, which are a relatively new concept in healthcare, describe the mindset that a patient is in, at a particular point in time, and are part of everyone’s experience as a human being.
- Medicine Affordability and Pricing – With medicine affordability and pricing continuing to be top priorities for action in many parts of the world, there’s been widespread public outcry to find price-lowering solutions that will expand access but not stifle innovation. In our report we examine several proposals.
- Value Assessment Frameworks – Value Assessment Frameworks (VAFs) are a new industry development for addressing questions related to the importance of pharmaceutical products and lay the groundwork for evidence-based decision making. Today, however, most existing VAFs continue to be a work in progress.
- Artificial Intelligence – Today, everyone is talking about artificial intelligence (AI). And the substance of those conversations continues to become stronger as we step deeper into the future. In healthcare, AI is helping to discover new medicines, designing its own clinical trials, and delivering a host of patient-centered technologies – such as biometric monitors, remote physician consultations and adherence assistance applications. It seems the possibilities for continued innovation are limitless. But what are the challenges?
- Real World Evidence – Acquiring a better understanding of how medicines are performing in real life situations is becoming an essential component for developing more effective medicines, delivering improved care to people, and creating more efficiency and value across the entire global healthcare system. However, access to real-world evidence (RWE) can be a real challenge for life sciences and pharmaceutical companies, governments and health regulators, despite its critical importance in the development and utilization of medicines and medical devices.
- Digital Health – For decades, a person’s relationship with their own health has been mostly a top-down affair – with physicians, institutions, hospitals and payors firmly in charge of decision-making. Today, however, a seismic shift in power control is well underway, as individual consumers are now calling the shots. This power shift is aided by innovations in digital health and major developments in mobile and connected technologies, which are transforming everything from how we communicate, source information and shop, to how we monitor our health and well being.